NASDAQ: IOSP · Specialty Chemicals

Innospec (IOSP) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Innospec (IOSP) at $79.13 a share. The stock last closed at $79.17, which puts the model's fair value 0.1% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Innospec Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$79.13midpoint of 2,000 simulations
Last close$79.17NASDAQ: IOSP
Gap to fair value-0.1%fair value against price
Model verdictFairly valuedevidence grade: High

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $76.71 to $79.13 (+3.2%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.

What the model makes of itThe price of $79.17 is level with it: Fairly valued, on a high evidence grade.

What's nextNext report on 16 Feb 2027. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give IOSP?

The calibrated range for IOSP over 63 trading days is $63.28 to $94.01. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $67.29 to $92.45. In 47% of the simulations the fair value came out above the price the model ran on.

$55.79$113.24
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $79.13. Dashed line: the last close, $79.17.

Faircurve Insights · 14 Nov 2026

Innospec Inc. is a global company headquartered in Englewood, Colorado. It focuses on the creation, production, formulation, promotion, and distribution of unique chemical products.

Faircurve's model put the fair value of Innospec at $79.13 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $76.71, so the fair value moved +3.2%. In the model's words, "The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move." The calibrated range over 63 trading days is $63.28 to $94.01. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence High. The grade reflects input completeness, peer count and agreement, and the spread of outcomes. It does not say whether the fair value is right.

Innospec scores 53 out of 100 on the model's overall quality measure, a composite of six factors. Three factors stand out. Balance sheet scores 100, with net debt to EBITDA of -0.98x against a peer median of 3.62x. Stability scores 100, with five-year EBITDA margin downside volatility of 0.5 pts against a peer median of 2.3 pts. Earnings quality scores 6, with FCF to net income of 0.30x against a peer median of 0.85x. The model compares Innospec with Minerals Technologies Inc. (MTX), Stepan Co (SCL), H.B. Fuller Company (FUL), Quaker Houghton (KWR) and Hawkins, Inc. (HWKN).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does IOSP report earnings, and how has the stock reacted?

Innospec's next earnings report is scheduled for 16 Feb 2027. Companies can move their dates.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across IOSP's last 8 reports, ignoring direction, was 4.6%.

0%5%10%15%20%no quote14.7%5 Nov '24no quote5.5%18 Feb '25no quote1.4%5 Aug '25no quote0.5%4 Nov '25no quote0.3%17 Feb '26no quote3.7%7 May '26no quote7.6%4 Aug '266.1%19.0%3 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

How does IOSP score on business quality?

Innospec's overall quality score is 53 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.5711.0%ROIC7.4%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).60.30xFCF / net income0.85x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.43-3.7%Revenue growth, trailing-2.2%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.570.7%Net buybacks / market value1.6%
Balance sheetNet debt to EBITDA and interest coverage.100-0.98xNet debt / EBITDA3.62x
StabilityDownside volatility of the EBITDA margin over the last five years.1000.5 ptsEBITDA margin downside volatility, 5y2.3 pts

How does IOSP compare with similar companies?

The companies in specialty chemicals closest to Innospec in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
CC The Chemours Company$12.48$13.12+5.1%Low evidence grade
MTX Minerals Technologies Inc.$60.57$65.44+8.0%Fairly valued
NGVT Ingevity Corporation$60.02$67.46+12.4%Low evidence grade
SCL Stepan Co$66.90$61.52-8.0%Fairly valued
FUL H.B. Fuller Company$49.00$54.04+10.3%Fairly valued
KWR Quaker Houghton$152.07$131.10-13.8%Fairly valued
WDFC WD-40 Company$226.01$208.49-7.8%Low evidence grade
HWKN Hawkins, Inc.$148.66$136.46-8.2%Fairly valued

What the comparable companies' multiples alone would give for IOSP, the peer-implied price, is $75.91 a share on this run. The fair value weighs that against the company's own multiple.

All specialty chemical stocks ranked by gap to fair value

Innospec at a glance

Innospec Inc., founded in 1938 as Octel Corp. and rebranded in January 2006, is a global company headquartered in Englewood, Colorado. It focuses on the creation, production, formulation, promotion, and distribution of unique chemical products.

Market value
$2.0B
Sector
Basic Materials
Industry
Specialty Chemicals
Revenue expected, next twelve months
$2.0B
Consensus revenue growth, next fiscal year
+7.7%
Analysts with estimates
2
Beta to the US market
0.33
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. IOSP was not among them.

How the fair value is worked out: the model prices Innospec on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for IOSP was $76.71. As of 14 Nov 2026 it is $79.13, a change of +3.2%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Innospec's valuation

Is Innospec stock undervalued or overvalued?

On Faircurve's model, IOSP reads as Fairly valued as of 14 Nov 2026. The model's fair value is $79.13 a share against a last close of $79.17, a gap of -0.1%.

What is IOSP's fair value?

$79.13 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $67.29 to $92.45.

What price range does the model give IOSP?

$63.28 to $94.01 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.

When does Innospec report earnings next?

The next report is scheduled for 16 Feb 2027. Companies can move their dates.

How much has IOSP moved on past earnings reports?

Across its last 8 reports the median two session move was 4.6%, ignoring direction. The largest was -19.0% around the report of 3 Nov 2026.

How confident is the model in this valuation?

The model's evidence grade for IOSP is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on IOSP

The model holds no idea open on IOSP today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on IOSP with their outcomes. A free account is enough.

Keep reading